bluebird bio, Inc. (BLUE)
NASDAQ: BLUE · IEX Real-Time Price · USD
1.220
-0.130 (-9.63%)
At close: Jul 17, 2024, 4:00 PM
1.200
-0.020 (-1.64%)
After-hours: Jul 17, 2024, 5:24 PM EDT

Company Description

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases.

Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.

The company’s clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with β-thalassemia.

It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010.

bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

bluebird bio, Inc.
bluebird bio logo
Country United States
Founded 1992
IPO Date Jun 19, 2013
Industry Biotechnology
Sector Healthcare
Employees 323
CEO Andrew Obenshain

Contact Details

Address:
455 Grand Union Boulevard
Somerville, Massachusetts 02145
United States
Phone 339-499-9300
Website bluebirdbio.com

Stock Details

Ticker Symbol BLUE
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001293971
CUSIP Number 09609G100
ISIN Number US09609G1004
SIC Code 2836

Key Executives

Name Position
Andrew Obenshain President, Chief Executive Officer and Director
Thomas J. Klima Chief Commercial Officer and Chief Operating Officer
Richard A. Colvin M.D., Ph.D. Chief Medical Officer
Christopher Krawtschuk CPA Chief Financial Officer, Principal Accounting Officer and Treasurer
Joseph D. Vittiglio Esq., J.D. Chief Legal and Business Officer and Secretary
Jess Rowlands Head of Corporate Communications
Andrea Walton Chief People Officer
Kasra Kasraian Senior Vice President of Technical Development and Operations
Scott Shoemaker Senior Vice President of Quality
Sarah Alspach Senior Vice President of External Affairs

Latest SEC Filings

Date Type Title
Jul 11, 2024 8-K Current Report
Jun 24, 2024 8-K Current Report
May 29, 2024 8-K Current Report
May 15, 2024 NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB
May 9, 2024 8-K Current Report
May 3, 2024 8-K Current Report
Apr 26, 2024 8-K Current Report
Apr 16, 2024 8-K Current Report
Apr 10, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Mar 26, 2024 8-K Current Report